85 completed, 8 terminated, 5 active not recruiting, 3 unknown. 106 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 106 | Completed 85, Terminated 8, Active not recruiting 5, Unknown 3, Withdrawn 3, Recruiting 2 |
| Phase 2 | 22 | Completed 19, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow HIV Infection: new trials by email Literature Review of HIV Infection trials Research Report on HIV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) MK-4646 - HIV Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2025-07-09 | 2026-06-22 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults VRC-HIVMAB0121-00-AB - HIV Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2024-10-07 | 2026-03-23 |
| Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial VB-201, Placebo - Inflammation, HIV Infection | Phase 1 / Phase 2 | Withdrawn | Priscilla Hsue, MD | 2022-07-01 | 2022-09-15 | |
| NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Efineptakin alfa - AIDS-Related Kaposi Sarcoma, HIV Infection | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 8 | 2022-05-23 | 2024-06-27 |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution - HIV Infection | Phase 1 | Completed | IrsiCaixa | 30 | 2022-03-30 | 2024-05-07 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 - HIV Infection | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 118 | 2021-05-21 | 2026-08-26 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 ABBV-181, Placebo - Human Immunodeficiency Virus (HIV), HIV Infection | Phase 1 | Completed | AbbVie | 41 | 2020-01-30 | 2023-03-09 |
| Study of Single IV Administration of P2G12 P2G12 Dose Cohort 1, P2G12 Dose Cohort 2, P2G12 Dose Cohort 3 - HIV Infection | Phase 1 | Unknown | St George's, University of London | 18 | 2019-08-01 | 2019-01-18 |
| Dual bNAb Treatment in Children ART, VRC01LS, 10-1074 - HIV Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2019-06-17 | 2026-05-04 |
| Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection Topical ABI-1968 cream - HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection | Phase 1 | Terminated | Antiva Biosciences | 6 | 2018-12-17 | 2019-07-24 |
| St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene Low dose naltrexone, Nalmefene - HIV Infection, Alcohol Use | Phase 1 / Phase 2 | Completed | Boston Medical Center | 11 | 2018-07-03 | 2020-08-24 |
| Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women Griffithsin Gel, Placebo Gel - HIV Infection | Phase 1 | Completed | Population Council | 15 | 2017-10-01 | 2018-11-27 |
| Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection ABI-1968 - HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection | Phase 1 | Completed | Antiva Biosciences | 57 | 2017-08-11 | 2019-02-07 |
| Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions FMT, Placebo - HIV Infection | Phase 1 / Phase 2 | Completed | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 30 | 2017-01-01 | 2018-10-30 |
| Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV - HIV Infection | Phase 1 | Completed | International AIDS Vaccine Initiative | 48 | 2016-11-01 | 2019-09-17 |
| Metformin Immunotherapy in HIV Infection Metformin - HIV Infection | Phase 1 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 22 | 2016-09-01 | 2023-03-14 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning - AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2016-06-22 | 2018-12-27 |
Showing 20 of 106. Sign in to see all of them.
HIV Infections (106) · Acquired Immunodeficiency Syndrome (15) · Lymphoma, Non-Hodgkin (6) · Sarcoma, Kaposi (6) · Anus Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Neoplasm Metastasis (4) · Burkitt Lymphoma (3) · Carcinoma, Hepatocellular (3) · Hepatitis C (3) · Hodgkin Disease (3) · Inflammation (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3)
Blood-Borne Infections (106) · Communicable Diseases (106) · Genital Diseases (106) · Urogenital Diseases (106) · Immune System Diseases (105) · Lentivirus Infections (105) · RNA Virus Infections (105) · Retroviridae Infections (105) · Sexually Transmitted Diseases (105) · Sexually Transmitted Diseases, Viral (105) · Immunologic Deficiency Syndromes (104) · Infections (104) · Virus Diseases (104) · Neoplasms (18) · Pathological Conditions, Signs and Symptoms (16)
Ritonavir (5) · Raltegravir Potassium (4) · Atazanavir Sulfate (3) · Cyclophosphamide (3) · Doxorubicin (3) · Etoposide (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · abacavir (3) · AIDSVAX (2) · Antiretroviral Therapy, Highly Active (2) · Aprepitant (2) · Biopsy (2) · Interleukin-2 (2) · Nevirapine (2)
National Cancer Institute (NCI) (16) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · International AIDS Vaccine Initiative (5) · St Stephens Aids Trust (4) · AIDS Malignancy Consortium (3) · Baylor College of Medicine (3) · GlaxoSmithKline (3) · University of Pennsylvania (3) · ANRS, Emerging Infectious Diseases (2) · Antiva Biosciences (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (2) · Merck Sharp & Dohme LLC (2) · National Institutes of Health Clinical Center (CC) (2)
United States (66) · United Kingdom (9) · Spain (7) · Canada (5) · France (5) · South Africa (5) · Australia (4) · Germany (3) · Puerto Rico (3) · Belgium (2) · Italy (2) · Netherlands (2) · Thailand (2) · Uganda (2) · Argentina (1)
Missak Haigentz (3) · Pablo Tebas, MD (3) · David Ho, MD (2) · Marta Boffito, Dr (2) · Mathias Lichterfeld, MD, PhD (2) · Michael Keefer, MD (2) · Soe Than, MD (2) · Winson Tang, M.D. (2) · Adriana Carvalhal, MD, PhD (1) · Alberto JS Duarte, Professor (1) · Amrita Krishnan (1)
PMID 26332605, PMID 31999736, PMID 40190112, PMID 10655111, PMID 11807307, PMID 15456731, PMID 15880120, PMID 17686878, PMID 18209043, PMID 18544020, PMID 19717722, PMID 20111582, PMID 20111599, PMID 20192810, PMID 20520820, PMID 20666584, PMID 20667889, PMID 21569187, PMID 22259028, PMID 22590502, PMID 22659241, PMID 23349878, PMID 23772623, PMID 23782005, PMID 24031012, PMID 24086333, PMID 24145880, PMID 24474568, PMID 24862215, PMID 25296098, PMID 25398137, PMID 25401780, PMID 25529885, PMID 25545673, PMID 25724985, PMID 25801562, PMID 26147010, PMID 26423811, PMID 26544853, PMID 26696749, PMID 26891037, PMID 27191165, PMID 27671833, PMID 28978797, PMID 29280762, PMID 29898870, PMID 30713538, PMID 30830886, PMID 31005944, PMID 31154457
U01CA121947 (8), UM1CA121947 (6), 2009 (2), P30CA015704 (2), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2019 (1), 2025 (1), R21AT004673 (1), R34MH077503 (1), U01AI110410 (1), U01CA154967 (1), U01CA183012 (1)